Birch Capital Management LLC Has $9.58 Million Stake in Novo Nordisk A/S $NVO

Birch Capital Management LLC grew its position in Novo Nordisk A/S (NYSE:NVO) by 2.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 138,758 shares of the company’s stock after acquiring an additional 2,764 shares during the quarter. Novo Nordisk A/S accounts for about 4.9% of Birch Capital Management LLC’s holdings, making the stock its 4th largest position. Birch Capital Management LLC’s holdings in Novo Nordisk A/S were worth $9,577,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Copeland Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock worth $27,000 after buying an additional 255 shares during the period. North Capital Inc. bought a new position in shares of Novo Nordisk A/S during the 1st quarter worth approximately $27,000. Stone House Investment Management LLC bought a new position in shares of Novo Nordisk A/S during the 1st quarter worth approximately $30,000. Disciplina Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 162.3% during the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after buying an additional 297 shares during the period. Finally, Spirit of America Management Corp NY bought a new position in shares of Novo Nordisk A/S during the 1st quarter worth approximately $35,000. Institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, September 29th. Weiss Ratings restated a “hold (c-)” rating on shares of Novo Nordisk A/S in a research report on Saturday, September 27th. Dbs Bank raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, August 22nd. Morgan Stanley cut Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and dropped their price target for the company from $59.00 to $47.00 in a report on Monday, September 29th. Finally, Barclays reaffirmed an “equal weight” rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.50.

Novo Nordisk A/S Trading Down 1.6%

NVO stock opened at $58.64 on Friday. The business has a fifty day moving average price of $55.26 and a 200 day moving average price of $63.33. The stock has a market capitalization of $261.83 billion, a price-to-earnings ratio of 16.11, a P/E/G ratio of 2.70 and a beta of 0.68. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $120.56. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.93 by $0.04. The company had revenue of $11.69 billion during the quarter, compared to analysts’ expectations of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were paid a $0.4119 dividend. This represents a dividend yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S’s dividend payout ratio (DPR) is 22.53%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.